Index

AAGL, 90–91, 96
morcellation Task Force of, 92
abarelix, 24
abdominal incision, for open
myomectomy, 56
abdominal scars, MRgFUS patient
selection and, 167–168
ablation. See magnetic-resonance-
guided focused ultrasound surgery
abnormal uterine bleeding (AUB), 1, 2
abruption, placental, 48
ACOG. See American College of
Obstetricians and Gynecologists
add-back therapy, for GnRH agonists,
24
adenomyoma, MRI of, 29–31
adenomyosis, ultrasonography
evaluation of, 18–20
adhesion prevention
after laparoscopic myomectomy,
83–85
after open myomectomy, 61–62
adhesions, after hysteroscopic
myomectomy, 122
adrenaline, for vaginal hysteroscopy,
151
actiology of uterine fibroids
classification systems, 10
definition, 1
epidemiology, 1–5
growth theories, 5–10
sarcomas, 10–11
age, uterine fibroid risk and, 2, 33
Agency for Healthcare Research and
Quality (AHRQ)
leiomyosarcoma prevalence
calculations of, 158–160
power morcellation outcome studies
of, 162–163
air embolism, during hysteroscopic
myomectomy, 121
AKAP13, 9
alcohol, uterine fibroid risk and, 4
American College of Obstetricians
and Gynecologists (ACOG), 90–91
Leiomyoma Morcellation Review
Group, 93–94, 96
anaemia, 1, 22
preoperative correction of, 55–56,
80, 100
anaesthesia, for outpatient
myomectomy, 143
analgesia, for outpatient myomectomy,
143
anastrozole, 25
for postmenopausal fibroids, 187
anti-adhesion agents, for laparoscopic
myomectomy, 83–85
arculate arteries, 69
aromatase, 7
postmenopausal fibroids and,
185
aromatase inhibitors, 25
for postmenopausal fibroids, 187
preoperative, 79–80
asoprisnil (J867), 6–7, 24
preoperative, 79
AUB. See abnormal uterine bleeding
basic fibroblast growth factor (bFGF),
7–8
Bendectin, 155–156
benign leiomyomatosis, 96
bFGF. See basic fibroblast growth
factor
bias, in prevalence rates, 156–157
bilateral uterine artery occlusion
(BUAO), 70–71
biopsy, myometrial, 108–110
bipolar resectoscope systems, 104–113,
138–142
bisphenol A, uterine fibroid risk and,
5
Black Women’s Health Study, 3–4
bleeding, 1, 10–11. See also
intraoperative bleeding control
at delivery, 45–46
after hysteroscopic myomectomy,
122
during hysteroscopic myomectomy,
120
postpartum, 46
submucosal fibroids causing, 136
UPA effects on, 23
after vaginal hysteroscopy, 153
vaginal hysterectomy for, 149
blood supply, uterine, 69
body mass index (BMI)
postmenopausal fibroids and, 185
uterine fibroid risk and, 3
bone health, postmenopausal fibroids
and, 185
Bonney’s Myomectomy Clamp, 57
breast implants, 156
broad ligament fibroids, in total
laparoscopic hysterectomy, 101
BUAO. See bilateral uterine artery
cocclusion
bulldog clips, 70
burns, during hysteroscopic
myomectomy, 120–121
caesarean hysterectomy, rate of, 46–47
caesarean section, rate of, 46
caffeine, uterine fibroid risk and, 3–4
calcified fibroids, 75
Campo Trophy hysteroscope, 106–108,
110–111
cancer. See also sarcoma
stages of development of, 5
carcinosarcoma, 10–11
Cardiovascular and Interventional
Radiological Society of Europe (CIRSE),
guidance for UFE, 180
CEE. See conjugated equine oestrogen
cell salvage, for blood loss reduction
during myomectomy, 59
cervical abnormalities, vaginal
hysteroscopy for, 149–150
cervical anaesthesia, for outpatient
myomectomy, 143
cervical fibroids, prolapsed, 141–142
cetrorelix, 24
cholesterol, 47
CIRSE. See Cardiovascular and
Interventional Radiological
Society of Europe
citrus fruits, 3
classification
fibroid research issues and, 37–38
for hysteroscopic resection, 104–115
systems of, 10, 14–15, 104–115, 126
ultrasonography evaluation and,
14–15
clinical presentation, 1
### Index

<table>
<thead>
<tr>
<th>Term</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>closure</td>
<td>for laparoscopic myomectomy, 73, 82–84, 113–115</td>
</tr>
<tr>
<td>for open myomectomy, 60–61</td>
<td></td>
</tr>
<tr>
<td>for robotic myomectomy, 73</td>
<td></td>
</tr>
<tr>
<td>for vaginal hysterectomy, 152</td>
<td></td>
</tr>
<tr>
<td>Cochrane guidance, for UFE, 180 cohort studies, 156</td>
<td></td>
</tr>
<tr>
<td>cold loop resectoscope technique, 74–75, 84, 94–96</td>
<td></td>
</tr>
<tr>
<td>colpotomy, 84</td>
<td></td>
</tr>
<tr>
<td>low corporeal fibroids and, 101–102</td>
<td></td>
</tr>
<tr>
<td>conception</td>
<td></td>
</tr>
<tr>
<td>intramural fibroids and, 34</td>
<td></td>
</tr>
<tr>
<td>submucosal fibroids and, 33–34</td>
<td></td>
</tr>
<tr>
<td>after UFE, 180–181</td>
<td></td>
</tr>
<tr>
<td>conjugated equine oestrogen (CEE), 4–5</td>
<td></td>
</tr>
<tr>
<td>postmenopausal fibroids and, 186–187 consent</td>
<td></td>
</tr>
<tr>
<td>for laparoscopic myomectomy, 80</td>
<td></td>
</tr>
<tr>
<td>for morcellation, 80, 96</td>
<td></td>
</tr>
<tr>
<td>for UFE, 174</td>
<td></td>
</tr>
<tr>
<td>containment bag, morcellation within, 74–75, 84, 94–96</td>
<td></td>
</tr>
<tr>
<td>contraception, postoperative, 61–62</td>
<td></td>
</tr>
<tr>
<td>contraceptives, uterine fibroid risk and, 4</td>
<td></td>
</tr>
<tr>
<td>coumarin, 122</td>
<td></td>
</tr>
<tr>
<td>counselling, for open myomectomy, 55–56</td>
<td></td>
</tr>
<tr>
<td>cytogenetics, 8</td>
<td></td>
</tr>
<tr>
<td>daVinci Surgical System, 65–68</td>
<td></td>
</tr>
<tr>
<td>DDT, uterine fibroid risk and, 5</td>
<td></td>
</tr>
<tr>
<td>decorin, 10</td>
<td></td>
</tr>
<tr>
<td>degarelix, 24</td>
<td></td>
</tr>
<tr>
<td>delivery</td>
<td></td>
</tr>
<tr>
<td>excessive blood loss at, 45–46 preterm, 47</td>
<td></td>
</tr>
<tr>
<td>Depo-MPA, 6</td>
<td></td>
</tr>
<tr>
<td>dermatopontin (DPT), 7</td>
<td></td>
</tr>
<tr>
<td>diagnosis</td>
<td></td>
</tr>
<tr>
<td>adenomyosis, 18–20 combined hysteroscopy and ultrasound, 106–108</td>
<td></td>
</tr>
<tr>
<td>fibroid research issues and, 37</td>
<td></td>
</tr>
<tr>
<td>leiomyosarcoma, 19–20</td>
<td></td>
</tr>
<tr>
<td>MRI, 18, 105–106</td>
<td></td>
</tr>
<tr>
<td>myometrial biopsy, 108–110</td>
<td></td>
</tr>
<tr>
<td>saline-infusion ultrasound, 17–19 three-dimensional ultrasound, 16–19</td>
<td></td>
</tr>
<tr>
<td>two-dimensional ultrasound, 15–16 diazepam, for outpatient myomectomy, 143</td>
<td></td>
</tr>
<tr>
<td>Diclegis, 155–156</td>
<td></td>
</tr>
<tr>
<td>diet, uterine fibroid risk and, 3</td>
<td></td>
</tr>
<tr>
<td>DPT. See dermatopontin</td>
<td></td>
</tr>
<tr>
<td>drains, for vaginal hysterectomy, 152–153</td>
<td></td>
</tr>
<tr>
<td>E2. See transdermal oestradiol</td>
<td></td>
</tr>
<tr>
<td>early pregnancy loss, 42–45</td>
<td></td>
</tr>
<tr>
<td>intramural fibroids and, 34</td>
<td></td>
</tr>
<tr>
<td>after myomectomy, 49–51</td>
<td></td>
</tr>
<tr>
<td>submucosal fibroids and, 33–34 after UAE, 51–52</td>
<td></td>
</tr>
<tr>
<td>EASI pump system, 110</td>
<td></td>
</tr>
<tr>
<td>ECM. See extracellular matrix</td>
<td></td>
</tr>
<tr>
<td>effectors of uterine fibroids, 7–8</td>
<td></td>
</tr>
<tr>
<td>elastolysis, 24–25</td>
<td></td>
</tr>
<tr>
<td>electrocautery, after fibroid extraction, 82–83</td>
<td></td>
</tr>
<tr>
<td>embolism, during hysteroscopic myomectomy, 121</td>
<td></td>
</tr>
<tr>
<td>embolization. See uterine artery embolization; uterine fibroid embolization</td>
<td></td>
</tr>
<tr>
<td>EMMY trial, 180</td>
<td></td>
</tr>
<tr>
<td>endometrial hyperplasia, vaginal hysterectomy for, 150</td>
<td></td>
</tr>
<tr>
<td>endometrial stromal sarcoma, 10–11</td>
<td></td>
</tr>
<tr>
<td>endometritis after hysteroscopic myomectomy, 122</td>
<td></td>
</tr>
<tr>
<td>after outpatient myomectomy, 144–145</td>
<td></td>
</tr>
<tr>
<td>endomyometritis, 47</td>
<td></td>
</tr>
<tr>
<td>endoscopic myomectomy, 67. See also laparoscopic myomectomy role of, 90–91</td>
<td></td>
</tr>
<tr>
<td>enhanced recovery after surgery (ERAS), 100–101</td>
<td></td>
</tr>
<tr>
<td>enucleation for laparoscopic myomectomy, 68–74, 82–83</td>
<td></td>
</tr>
<tr>
<td>for open myomectomy, 59–62</td>
<td></td>
</tr>
<tr>
<td>for robotic myomectomy, 68–74</td>
<td></td>
</tr>
<tr>
<td>for total laparoscopic hysterectomy, 102</td>
<td></td>
</tr>
<tr>
<td>epidemiology of uterine fibroids, 1–5</td>
<td></td>
</tr>
<tr>
<td>ERAS. See enhanced recovery after surgery</td>
<td></td>
</tr>
<tr>
<td>ERBB2, 7–8</td>
<td></td>
</tr>
<tr>
<td>ergonomics, for total laparoscopic hysterectomy, 102</td>
<td></td>
</tr>
<tr>
<td>ERTS. See oestrogen receptors</td>
<td></td>
</tr>
<tr>
<td>erythropoietin, 80</td>
<td></td>
</tr>
<tr>
<td>European Society of Hysteroscopy, classification system, 10</td>
<td></td>
</tr>
<tr>
<td>evidence-based medicine basics of, 156–157 history of, 155–156 exercise, uterine fibroid risk and, 3</td>
<td></td>
</tr>
<tr>
<td>expanded polytetrafluoroethylene, 84–85</td>
<td></td>
</tr>
<tr>
<td>extracellular matrix (ECM), 10</td>
<td></td>
</tr>
<tr>
<td>fadrozole, 25</td>
<td></td>
</tr>
<tr>
<td>familial expression of fibroids, 8</td>
<td></td>
</tr>
<tr>
<td>fatty degeneration, MRI of, 29, 31</td>
<td></td>
</tr>
<tr>
<td>FDA. See Food and Drug Administration female sex hormones pharmacologic treatment and, 22</td>
<td></td>
</tr>
<tr>
<td>uterine fibroid growth promotion by, 5–6</td>
<td></td>
</tr>
<tr>
<td>FEMME trial, 181</td>
<td></td>
</tr>
<tr>
<td>fertility, 33, 35, 38, 78</td>
<td></td>
</tr>
<tr>
<td>fibroid location impact on, 38–40</td>
<td></td>
</tr>
<tr>
<td>fibroid number impact on, 41–42</td>
<td></td>
</tr>
<tr>
<td>fibroid size impact on, 40–41</td>
<td></td>
</tr>
<tr>
<td>HIFU and thermal ablation for enhancement of, 52</td>
<td></td>
</tr>
<tr>
<td>intramural fibroids and, 34, 38–40, 126</td>
<td></td>
</tr>
<tr>
<td>mechanisms of fibroid impacts on, 33</td>
<td></td>
</tr>
<tr>
<td>after MRgFUS, 169–170</td>
<td></td>
</tr>
<tr>
<td>myomectomy for enhancement of, 49–51</td>
<td></td>
</tr>
<tr>
<td>submucosal fibroids and, 33–34</td>
<td></td>
</tr>
<tr>
<td>HIFU, FBI, P-V, uterine fibroids, 33–34, 38–40, 135–136</td>
<td></td>
</tr>
<tr>
<td>subserosal fibroids and, 34–35, 38–40</td>
<td></td>
</tr>
<tr>
<td>UAE for enhancement of, 51–52</td>
<td></td>
</tr>
<tr>
<td>after UFE, 180–181</td>
<td></td>
</tr>
<tr>
<td>ultrasonography evaluation and, 14</td>
<td></td>
</tr>
<tr>
<td>Fibrin sheet, 84–85</td>
<td></td>
</tr>
<tr>
<td>FIGO. See International Federation of Gynecology and Obstetrics</td>
<td></td>
</tr>
<tr>
<td>fibroid localization, 40, 135–136</td>
<td></td>
</tr>
<tr>
<td>5 French instruments, 104–124, 138–139</td>
<td></td>
</tr>
<tr>
<td>flax, uterine fibroid risk and, 5</td>
<td></td>
</tr>
<tr>
<td>FlexDex needle driver, 65</td>
<td></td>
</tr>
<tr>
<td>FloSeal™, for blood loss reduction</td>
<td></td>
</tr>
<tr>
<td>during myomectomy, 59</td>
<td></td>
</tr>
<tr>
<td>fluid management, for outpatient myomectomy, 142–143</td>
<td></td>
</tr>
<tr>
<td>fluid overload syndrome during hysteroscopic myomectomy, 118–120</td>
<td></td>
</tr>
<tr>
<td>during outpatient myomectomy, 145–146</td>
<td></td>
</tr>
<tr>
<td>Food and Drug Administration (FDA) leiomyosarcoma prevalence calculations of, 155–160</td>
<td></td>
</tr>
<tr>
<td>morcellation Safety Communication Report of, 74, 92–94</td>
<td></td>
</tr>
<tr>
<td>MRgFUS approval by, 165</td>
<td></td>
</tr>
<tr>
<td>power morcellation outcome studies of, 160–163</td>
<td></td>
</tr>
</tbody>
</table>
ganirelix, 24
gelatin fibrin matrix, for blood loss reduction during myomectomy, 59
genetics, 8–10
genomic screening, 9
gonadotrophin-releasing hormone (GnRH) agonists, 5, 23–24, 184
for blood loss reduction during myomectomy, 56–58
preoperative, 56, 79–80, 100, 110, 128, 150, 168
gonadotrophin-releasing hormone (GnRH) antagonists, 6, 24–25
Gore-Tex®, 84–85
green tea extract, 3
growth rates of, 1–2
theories of, 5–10
growth factors, 7–8
gynaecology, evidence-based medicine in, 155–157
haemorrhage. See bleeding
haemorrhagic degeneration, MRI of, 28–30
haemostasis techniques
after fibroid extraction, 82–83
for laparoscopic myomectomy, 57–59, 69–72, 81–82
for open myomectomy, 56–59
for robotic myomectomy, 69–72
haemostatic suture, for blood loss reduction during myomectomy, 57
heavy menstrual bleeding (HMB), 1, 22
hereditary, 8
hereditary leiomyomatosis and renal cell cancer (HLRCC), 10–11
high-intensity focused ultrasound (HIFU), for reproductive enhancement, 52
HLRCC. See hereditary leiomyomatosis and renal cell cancer
HMB. See heavy menstrual bleeding
HMGA2 mutations, 9–10
HOPEFUL trial, 181
hormone receptors, 8, 22
hormone replacement therapy (HRT)
postmenopausal fibroids and, 186–187
uterine fibroid risk and, 4–5
HPV. See human papilloma virus
HRT. See hormone replacement therapy
HSG. See hysterosalpingogram
human papilloma virus (HPV), 10
hydromassage, 113
2-hydroxyestrone metabolites, 2–3
16α-hydroxyestrone metabolites, 2–3
hyperemesis gravidarum, 155–156
hyperhydration, during hysteroscopic myomectomy, 118–120
hyponatraemia, during hysteroscopic myomectomy, 118–120
hysterectomy. See also vaginal hysterectomy
caesarean, 46–47
indications for, 99, 149–150
minimally invasive, 90–91, 93–94
trends in, 93–94
Hysterosalpingogram (HSG), diagnosis with, 37–38
hysteroscopic 5 French bipolar needle electrodes, 104–124, 138–139
hysteroscopic myomectomy, 104, 123
combined approach to resection, 109–117
combined hysteroscopic and ultrasound diagnosis for, 106–108
dissection and removal, 114–115
excision by two-step procedure, 117
fibroid classification for, 104–115
instrumentation for, 110–111
for intramural fibroids, 127–128
intraoperative complications of, 117–121
laparoscopic guidance for, 127–128
laparoscopic myomectomy for, 127–128
MRI diagnosis for, 105–106
myometrial biopsy for, 108–110
operative techniques for intramural myoma, 128–129
postoperative complications of, 122
postoperative management of, 131–133
preoperative treatment for, 110, 128
resectoscope resection, 111–115
shaver resection, 115
surgical steps for intramural myoma removal, 129–132
surgical strategy in, 110–111
ultrasoundography guidance for, 128–129
uterine contraction induction for, 128–129
hysterectomy, diagnosis with, 38, 106–108
IBS shaver, 111, 115
implantation
intramural fibroids and, 34
submucosal fibroids and, 33–34
incision for hysteroscopic myomectomy of intramural fibroids, 130
for laparoscopic myomectomy, 72–73, 82
for open myomectomy, 56, 59
for robotic myomectomy, 72–73
single versus multiple, 59
for vaginal hysterectomy, 151
infection, postoperative, 47, 122, 144–145, 153–154
infertility, 33, 35, 38, 78
fibroid location impact on, 38–40
fibroid number impact on, 41–42
fibroid size impact on, 40–41
HIFU and thermal ablation for, 52
intraproabal fibroids and, 34, 38–40
mechanisms of fibroid role in, 33
after MRFUS, 169–170
myomectomy for, 49–51
submucosal fibroids and, 33–34, 38–40, 135–136
subserosal fibroids and, 34–35, 38–40
UAE for, 51–52
after UAE, 180–181
ultrasoundography evaluation and, 14
inhaled nitrous oxide, for outpatient myomectomy, 143
inherence, 8
initiation of uterine fibroids, 5
injury hypothesis, 5
instrumentation
for hysteroscopic, 110–111
laparoscopic, 65, 68–69
MRFGUS, 168–169
for outpatient myomectomy, 138–142
robotic, 65–69
Interceed®, 84–85
International Federation of Gynecology and Obstetrics (FIGO), 187
leiomyoma classification system, 10, 14–15, 104–115, 126
interposed bowel, MRFGUS patient selection and, 167
intracervical blocks, for outpatient myomectomy, 143
intraproabal fibroids, 133
classification of, 14–15, 37–38, 126
fertility and, 34, 38–40, 126
hysteroscopic myomectomy suitability for, 127–128
indications for removal of, 126–127
laparoscopic guidance for removal of, 129
location of, 128, 130
operative techniques for, 128–129
postoperative management of, 131–133
preoperative assessment and medication for, 128
Index

intramural fibroids (cont.)
surgical steps for removal of, 129–132
ultrasonography guidance for removal of, 128–129
uterine contraction induction for, 128–129
intraoperative bleeding control for laparoscopic myomectomy, 57–59, 69–72, 81–82
during open myomectomy, 56–59
for robotic myomectomy, 69–72
intrauterine adhesions (IUA), after hysteroscopic myomectomy, 122
intrauterine growth restriction (IUGR), 47
iron supplements, preoperative, 55–56, 80, 100
isolation bag, morcellation within, 74–75, 84, 94–96
IUA. See intrauterine adhesions
IUGR. See intrauterine growth restriction
IVF
intramural fibroids and, 34
submucosal fibroids and, 33–34
J867. See asoprisnil
junctional zone (JZ) myometrium, 104–106
labour
dysfunctional, 46
preterm, 47
Lahey bag, morcellation within, 74–75
laparoscopic assisted myomectomy, 68–75
laparoscopic assisted vaginal myomectomy, 75
laparoscopic guidance, for hysteroscopic myomectomy of intramural fibroids, 129
laparoscopic hysterectomy. See also total laparoscopic hysterectomy
history of, 99
indications for, 99
role of, 90–91
subtotal, 99, 102
trends in, 93–94
laparoscopic myomectomy (LM), 78, 86
anaemia correction for, 80
anti-adhesion agents for, 83–85
bleeding control techniques for, 57–59, 69–72, 81–82
complications of, 85
consent procedure for, 80
current state of, 67
enucleation for, 68–74, 82–83
incision placement for, 72–73
indications for, 65, 78
medical pretreatment for, 79–80
morcilation for, 68–74, 83–85
open myomectomy versus, 86
port placement for, 68–69
preoperative assessment and planning for, 78–79
preoperative imaging for, 79
preparation in operating theatre, 80
procedure planning for, 67–75
robot-assisted, 85–86
role of, 90–91
surgical technique for, 80–85
trends in, 93–94
trocars placement, 80–81
uterine closure for, 73, 82–84
uterine incision for, 72–73, 82
laparoscopic subtotal hysterectomy (LASH), 99, 102
laparoscopic uterine artery occlusion (LUAO), 51
laparotomy, 55, 62
abdominal incision, 56
adhesion prevention, 61–62
blood loss reduction techniques, 56–59
closure, 60–61
complications of, 57–62
enucleation, 59–62
indications for, 55
microsurgical principles for, 56
postoperative care, 61–62
preoperative counselling and preparation for, 55–56
uterine incision, 59
LASH. See laparoscopic subtotal hysterectomy
lateral fibroids, in total laparoscopic hysterectomy, 101
Leiomyoma Morcellation Review Group, 93–94, 96
leiomyoma stem cells, 9–10
leiomyomas. See uterine fibroids
leiomyomatosis, benign, 96
leiomyosarcoma (LMS), 163–164
postmenopausal fibroids and, 185–186
prevalence of, 155–160, 163
ultrasoundography evaluation of, 19–20
leiomyosarcoma (LMS) morcellation debate, 68–74, 84, 90–94, 96, 163–164
current controversy surrounding, 156
data disparities involving, 158–160
evidence-based medicine basics and, 156–157
evidence-based medicine history and, 155–156
history of, 155
meta-analysis utility for, 157–158
outcomes after morcellation, 160–163
postmenopausal fibroids and, 186
timeline of, 91–94
letrozole, 25
preoperative, 79–80
leuprolide, 23–24
preoperative, 79
LM. See laparoscopic myomectomy
LMS. See leiomyosarcoma
local anaesthetic, for outpatient myomectomy, 143
low corporeal fibroids, in total laparoscopic hysterectomy, 101–102
LUAO. See laparoscopic uterine artery occlusion
magnetic resonance-guided focused ultrasound surgery (MRgFUS), 165, 170
complications of, 169
fertility outlook after, 169–170
history of, 165
mechanism of, 165
outcomes of, 170
patient preparation for, 168–169
patient selection for, 165–168
platforms for, 168–169
procedure for, 169
recovery after, 169
treatment success measurement for, 165
magnetic resonance imaging (MRI) advantages of, 28
diagnosis with, 18, 105–106
fibroid features on, 28–31
fibroid mimickers on, 30–32
fibroid research issues and, 38
junctional zone myometrium on, 104–106
preoperative, 79, 100, 128
sarcomas on, 19–20, 29–31
technique of, 28
for UFE, 175–176
malignancy. See leiomyosarcoma
morcilation debate
malignant transformation, 5
malpresentation, 46
manual morcellation. See also leiomyosarcoma morcellation debate
history of, 91
for laparoscopic and robotic myomectomy, 74
morcellation, 90, 96. See also leiomyosarcoma morcellation debate
complications of, 96
consent for, 80, 96
history of, 91–94
improvement measures for, 96
for laparoscopic myomectomy, 68–74
outcomes after, 160–163
for robotic myomectomy, 68–74
role of minimally invasive surgery and, 90–91
tissue extraction options for, 94–95
for total laparoscopic hysterectomy, 102
mortality, 1
M. See medroxyprogesterone acetate
MRgFUS. See magnetic resonance-guided focused ultrasound surgery
MRI. See magnetic resonance imaging
MUSA group consensus, 15–16
mutations, 9–10
myomas. See uterine fibroid myomectomy. See also hysteroscopic myomectomy; laparoscopic myomectomy; open myomectomy; outpatient myomectomy; robotic myomectomy
indications for, 55, 65, 78, 135–136
minimally invasive, 67, 90–91
for reproductive enhancement, 49–51
trends in, 93–94
myometrial biopsy, 108–110
myometrial defect repair for laparoscopic myomectomy, 73, 82–84
for open myomectomy, 60–61
myometrial free margin, 127
MynSure® tissue removal system, 140–141
National Institute of Environmental Health Sciences Uterine Fibroid Study, 3–4
natural orifice morcellation, for laparoscopic and robotic myomectomy, 75
necrosis, MRI of, 28, 30
NICCE guidance, for UFE, 179
nitrous oxide, for outpatient myomectomy, 143
non-perfused volume (NPV), 165
non-steroidal anti-inflammatory drug (NSAID), for outpatient myomectomy, 143
NPV. See non-perfused volume
NSAID. See non-steroidal anti-inflammatory drug
Nurses’ Health Study II, 4
OBE2109, 24–25
obesity
MRgFUS patient selection and, 166
postmenopausal fibroids and, 185
uterine fibroid risk and, 3
OCs. See oral contraceptives
oestriodiol, 4–5
postmenopausal fibroids and, 186–187
uterine fibroid growth promotion by, 5–6
oestrogen, 184
pharmacologic treatment and, 22
postmenopausal fibroids and, 185
uterine fibroid risk and, 3
pharmacologic treatment and, 22
potassium chloride, for outpatient
postmenopausal fibroids and, 185
uterine fibroid growth promotion by, 5–6
postoperative care, 61
preoperative bleeding, for open myomectomy, 60
preoperative counselling and preparation for, 55–56
uterine incision, 59
opioids, for outpatient myomectomy, 143
oral contraceptives (OCs), uterine fibroid risk and, 4
Ornipressin, for bleeding, 120
osteoporosis, postmenopausal fibroids and, 185
outpatient myomectomy, 135–136, 146
analgesia and anaesthesia for, 143
complications of, 144–146
facilities for, 144–146
fluid management for, 142–143
indications for, 135–136
operating devices and instruments for, 138–142
size and position considerations in, 136–138
training for, 145–146

© in this web service Cambridge University Press

www.cambridge.org

Cambridge University Press
978-1-108-42017-4 — Modern Management of Uterine Fibroids
Edited by Mostafa Metwally, Tin-Chiu Li
Index

More Information

Edited by Mostafa Metwally, Tin-Chiu Li
978-1-108-42017-4 — Modern Management of Uterine Fibroids
Cambridge University Press

© in this web service Cambridge University Press

www.cambridge.org

Cambridge University Press
978-1-108-42017-4 — Modern Management of Uterine Fibroids
Edited by Mostafa Metwally, Tin-Chiu Li
Index

More Information
Index

ovarian fibroma, MRI of, 30–32
ovarian steroid hormones, 184
oxidized regenerated cellulose, 84–85
oxytocin
for bleeding, 120
for blood loss reduction during
myomectomy, 58
for hysteroscopic myomectomy of
intramural fibroids, 128
PAECs. See progesterone receptor
modulator-associated endometrial
changes
PALM-COEIN classification system,
10
Palmer's point, 68, 80–81, 101
paracervical blocks, for outpatient
myomectomy, 143
paracervical mechanical clamp, for
blood loss reduction during
myomectomy, 57
parity, uterine fibroid risk and, 4
pathophysiology of uterine fibroids, 1
classification systems, 10
definition, 1
epidemiology, 1–5
growth theories, 5–10
sarcomas, 10–11
patient selection
for MRFUS, 165–168
for UFE, 173–174
PEARL studies, 23
pelvic anatomy assessment, for total
laparoscopic hysterectomy, 101–102
pelvic organ prolapse, vaginal
hysterectomy for, 149
pelvic pain, vaginal hysterectomy for,
150
pelvic pathology, concurrent, 100
perforation
during hysteroscopic myomectomy,
117–118
during outpatient myomectomy, 144
pharmacologic treatment, 22, 25
aromatase inhibitors, 25, 79–80, 187
female sex hormones and, 22
 GnRH agonists, 5, 23–24, 56–58,
79–80, 100, 110, 128, 150, 168, 184
 GnRH antagonists, 6, 24–25
role of, 22
SERMs, 8, 25, 187–188
SPRM, 6–7, 22–24, 56, 79–80, 100
phthalates, uterine fibroid risk and, 5
phyto-oestrogens, uterine fibroid risk
and, 5
pirfenidone, 8–9
Pitressin®, for blood loss reduction
during myomectomy, 81–82
placenta accreta, after hysteroscopic
myomectomy, 123
placenta previa, 47–48
placental abruption, 48
polychlorinated biphenyls, uterine
fibroid risk and, 5
port placement
for laparoscopic myomectomy,
68–69, 80–81
for robotic myomectomy, 68–69
for total laparoscopic hysterectomy,
101
postmenopausal fibroids, 184–185, 188
aromatase enzyme expression and, 185
aromatase inhibitors for, 187
BMI and, 185
bone health and, 185
HRT effects on, 186–187
leiomyosarcoma and, 185–186
management of, 187–188
rare cases of, 186
SERMs for, 187–188
UAE for, 188
postmenopause, 184
postoperative care, for open
myomectomy, 61–62
postoperative infection, 47, 122,
144–145, 153–154
postoperative management, of
hysteroscopic myomectomy,
131–133
postpartum haemorrhage, 46
power morcellation, 90, 96.
postoperative infection, 47, 122,
144–145, 153–154
postoperative management, of
hysteroscopic myomectomy,
131–133
postpartum haemorrhage, 46
power morcellation, 90, 96.
see also leiomyosarcoma morcellation
debate
complications of, 96
history of, 91–94
improvement measures for, 96
for laparoscopic myomectomy,
68–74, 83–85
outcomes after, 160–163
for robotic myomectomy, 68–74
role of minimally invasive surgery
and, 90–91
tissue extraction options for,
94–95
PPROM. See preterm premature
rupture of membranes
PR. See progesterone receptor
pregnancy
early loss of, 33–34, 42–45, 49–52
fibroid location impact on, 38–40
fibroid size impact on, 40–41
HIFU and thermal ablation for
enhancement of, 52
intramural fibroids and, 34, 38–40,
126
late complications of, 45
after MRFUS, 169–170
myomectomy for enhancement of,
49–51
submucosal fibroids and, 33–34,
38–40, 135–136
UAE for enhancement of, 51–52
after UFE, 180–181
UPA in, 23
uterine fibroid risk and, 4
premature rupture of membranes
(PROM), 48
preoperative preparation
for hysteroscopic myomectomy, 110,
128
for intramural fibroids, 128
for laparoscopic myomectomy,
78–80
for MRFUS, 168–169
for open myomectomy, 55–56
for total laparoscopic hysterectomy,
100–101
for vaginal hysterectomy, 150
preoperative uterine artery
eMBOLIZATION (PUAE), 69
preprocedure analgesia, for outpatient
myomectomy, 143
preterm delivery (PTD), 47
preterm labour (PTL), 47
preterm premature rupture of
membranes (PPROM), 48–49
prevalence, 1
bias in, 156–157
of leiomyosarcoma, 155–160, 163
Proplex. See telapristone acetate
progesterone, 184
pharmacologic treatment and, 22
uterine fibroid growth promotion by,
5–6
progesterone receptor modulator-
associated endometrial changes
(PAECA), 23–24
progesterone receptors (PRs), 8, 22, 184
progestins, 6
progression of uterine fibroids, 5–7
prolapsed cervical fibroids, 141–142
PPROM. See premature rupture of
membranes
promotion of uterine fibroids, 5–7
prospective data collection, 156–157
PRs. See progesterone receptors
PTD. See preterm delivery
PTL. See preterm labour
PUAE. See preoperative uterine artery
embolization
race, uterine fibroid risk and,
2–3
RALM. See robot-assisted laparoscopic
myomectomy
raloxifene, 8, 25, 187–188
<table>
<thead>
<tr>
<th>Topic</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>recombinant erythropoietin, 80</td>
<td>75</td>
</tr>
<tr>
<td>recovery enhanced, 100–101 after MRgFUS, 169</td>
<td></td>
</tr>
<tr>
<td>recurrence, after open myomectomy, 62 red degeneration, MRI of, 28–30</td>
<td></td>
</tr>
<tr>
<td>relugolix (TAK-385), 24–25</td>
<td></td>
</tr>
<tr>
<td>reproductive outcomes, 37. See also infertility</td>
<td></td>
</tr>
<tr>
<td>caesarean hysterectomy, 46–47</td>
<td></td>
</tr>
<tr>
<td>caesarean section rate, 46 chorioamnionitis and endomymetritis, 47</td>
<td></td>
</tr>
</tbody>
</table>
### Index

<table>
<thead>
<tr>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>198</td>
</tr>
</tbody>
</table>

thermal ablation, for reproductive enhancement, 52  
three-dimensional ultrasound diagnosis with, 16–19  
preoperative fibroid mapping with, 56, 79, 128  
tibolone, 187  
TLH. See total laparoscopic hysterectomy (TLH), 99, 102  
indications and contraindications for, 99  
inhae in operative challenges of, 101–102  
preoperative challenges of, 100–101  
procedure and complications of, 99–100  
tourniquets, for blood loss reduction during myomectomy, 57  
tramadol, for outpatient myomectomy, 143  
trixane onic acid, for blood loss reduction during myomectomy, 58  
transdermal oestradiol (E2), 4–5  
trocar placement, for laparoscopic myomectomy, 68–69, 80–81  
Trophy hysteroscope, 106–124  
TruClear™ tissue removal system, 115, 138–140  
two-dimensional ultrasound, diagnosis with, 15–16  
UAE. See uterine artery embolization  
UEF. See uterine fibroid embolization  
UFs. See uterine fibroids  
ulipristal acetate (UPA), 6, 23–24  
preoperative, 56, 79–80, 100, 110  
ULTRA Mini device™, 140  
ultrasonography evaluation, 14, 20  
adonemysosarcoma, 18–20  
diagnosis with combined hysteroscopy, 106–108  
diagnosis with saline-infusion ultrasound, 17–19  
diagnosis with three-dimensional ultrasound, 16–19  
diagnosis with two-dimensional ultrasound, 15–16  
fibroid classification and, 14–15  
ibroid research issues and, 155  
leiomysarcomas, 19–20  
MRI evaluation and, 18  
preoperative, 56, 79, 100, 128  
ultrasonography guidance, for hysteroscopic myomectomy of intramural fibroids, 128–129  
ultrasound lysis. See magnetic-resonance-guided focused ultrasound surgery  
UPA. See ulipristal acetate  
uterine arteries, 69  
uterine artery embolization (UAE) for blood loss reduction during myomectomy, 58, 69  
for postmenopausal fibroids, 188  
for reproductive enhancement, 51–52  
uterine artery ligation/occlusion for blood loss reduction during myomectomy, 57, 70–72  
uterine closure for laparoscopic myomectomy, 73, 82–84  
for open myomectomy, 60–61  
for robotic myomectomy, 73  
uterine contractions, induction of, 128–129  
uterine fibroid embolization (UFE), 173  
anaomy and patient selection for, 173–174  
background and history of, 173  
clinic and consent for, 174  
clinical trials overview for, 180–181  
complications of, 179  
conception after, 180–181  
future developments in, 182  
guidance and body of literature of, 179–180  
imageing for, 175–176  
surgery combined with, 182  
technique of, 175–179  
uterine fibroids (UFs), 184  
blood vessels of, 69  
classification of, 10, 14–15, 37–38, 104–115, 126  
clinical presentations of, 1, 22, 78  
definition of, 1  
effectors of, 7–8  
epidemiology of, 1–5  
fertility effects of, 33  
formation and growth of, 5–6  
genetic findings of, 8–10  
growth rates of, 1–2  
growth theories of, 5–10  
initation of, 5  
issues with research on, 37–38  
location of, 38–40, 128, 130, 136–138, 166  
menopause and, 4, 184–186  
morbidity caused by, 1  
number of, 41–42  
ovarian steroid hormones and, 184  
pathophysiology and aetiology of, 1–11  
prevalence of, 1  
promotion and progression of, 5–7  
recurrence of, 62  
risk factors for, 1–5, 7, 33  
sarcomas, 10–11  
sized of, 40–41, 136–138, 166, 168  
surgical options for, 55, 78  
vascularity of, 166, 168  
uterine incision for hysteroscopic myomectomy of intramural fibroids, 130  
for laparoscopic myomectomy, 72–73  
for open myomectomy, 59  
for robotic myomectomy, 72–73  
uterine perforation during hysteroscopic myomectomy, 117–118  
during outpatient myomectomy, 144  
uterine rupture after hysteroscopic myomectomy, 122  
after open myomectomy, 62  
uterotonic agents, for blood loss reduction during myomectomy, 58  
uterus removal, for total laparoscopic hysterectomy, 99, 102  
vaginal coring, 75  
vaginal hysterectomy, 99, 153–154  
advantages of, 149  
complications of, 153  
history of, 149  
indication for, 149–150  
preoperative assessment for, 150  
procedure for, 150–153  
role of, 90–91  
trends in, 93–94  
vascular supply, uterine, 69  
vascularity, MRgFUS patient selection and, 166, 168  
vasopressin for blood loss reduction during myomectomy, 57–58, 69, 81–82  
for hysteroscopic myomectomy of intramural fibroids, 128  
in total laparoscopic hysterectomy, 101  
vaginal episodes, during outpatient myomectomy, 145  
vegetarians, uterine fibroid risk in, 3–11  
vilaprisan, 24  
vitamin D, 3  
warfarin, 122  
WHO. See World Health Organization  
Wnt/β-catenin pathway, 9–10  
World Health Organization (WHO), leiomysarcoma criteria of, 159–160  
xeno-oestrogens, uterine fibroid risk and, 5